

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

Hep-55.1C

RRID:CVCL_5766

Type: Cell Line

Proper Citation

CLS Cat# 400201, RRID:CVCL_5766

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5766

Proper Citation: CLS Cat# 400201, RRID:CVCL_5766

Description: Cell line Hep-55.1C is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Hepatocellular carcinoma of the mouse

Defining Citation: [PMID:1382443](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Hep-55.1C

Synonyms: HEP-55.1C, 55.1C

Cross References: CLS:400201, Wikidata:Q54882767

ID: CVCL_5766

Vendor: CLS

Catalog Number: 400201

Record Creation Time: 20220624T070800+0000

Record Last Update: 20260830T000510+0000

Ratings and Alerts

No rating or validation information has been found for Hep-55.1C.

No alerts have been found for Hep-55.1C.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Li X, et al. (2025) IFN γ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma. *Cell death & disease*, 16(1), 512.

Cheng HW, et al. (2024) Manipulating the Crosstalk between Cancer and Immunosuppressive Cells with Phototherapeutic Gold-Nanohut for Reprogramming Tumor Microenvironment. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 11(32), e2404347.

Giraud J, et al. (2024) THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1. *Cell reports*, 43(2), 113773.

Qiang N, et al. (2023) Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma. *International immunopharmacology*, 118, 110068.

Mender I, et al. (2023) Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma. *Molecular cancer therapeutics*, 22(6), 737.

Tsao HY, et al. (2022) Dual-Sensitive Gold-Nanocubes Platform with Synergistic Immunotherapy for Inducing Immune Cycle Using NIR-Mediated PTT/NO/IDO. *Pharmaceuticals (Basel, Switzerland)*, 15(2).

Cheng HW, et al. (2021) Ansamitocin P3-Loaded Gold-NanoCage Conjugated with Immune Checkpoint Inhibitor to Enhance Photo-Chemo-Thermal Maturation of Dendritic Cells for Hepatocellular Carcinoma. *Polymers*, 13(16).

Metzger P, et al. (2018) Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. *Scientific reports*, 8(1), 8810.